KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Gross Margin (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Gross Margin for 13 consecutive years, with 89.13% as the latest value for Q4 2025.

  • Quarterly Gross Margin rose 411.0% to 89.13% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 89.63% through Dec 2025, up 140.0% year-over-year, with the annual reading at 89.63% for FY2025, 140.0% up from the prior year.
  • Gross Margin for Q4 2025 was 89.13% at Supernus Pharmaceuticals, down from 90.13% in the prior quarter.
  • The five-year high for Gross Margin was 90.13% in Q3 2025, with the low at 82.29% in Q2 2021.
  • Average Gross Margin over 5 years is 87.6%, with a median of 88.15% recorded in 2023.
  • The sharpest move saw Gross Margin tumbled -1109bps in 2021, then soared 568bps in 2022.
  • Over 5 years, Gross Margin stood at 89.32% in 2021, then decreased by -3bps to 86.28% in 2022, then increased by 2bps to 88.06% in 2023, then fell by -3bps to 85.01% in 2024, then rose by 5bps to 89.13% in 2025.
  • According to Business Quant data, Gross Margin over the past three periods came in at 89.13%, 90.13%, and 89.83% for Q4 2025, Q3 2025, and Q2 2025 respectively.